title: A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.
abstract: BACKGROUND
  Efficacy of recombinant adenovirus serotype 5 (rAd5) vaccine vectors for human immunodeficiency virus type 1 (HIV-1) and other pathogens have been shown to be limited by high titers of pre-existing Ad5 neutralizing antibodies (NAbs) in the developing world.
  
  
  RESULTS
  Using a secreted embryonic alkaline phosphatase (SEAP) neutralization assay, 50% serum neutralization titers against rAd2 and rAd5 vectors were measured in samples from 274 infants and young children in northeast China. The pediatric population was found to be 59.6% and 43.3% seropositive for rAd2 and rAd5, respectively. Of all participants, 44.9% had moderate and high (> 200) and 25.6% had high (>1000) Ad2 NAb titers, compared with the corresponding rates of 26.6% and 9.3% against Ad5. Marked age-dependent increases in NAb titers to both Ad serotypes were observed across five age groups, with the exception of infants in the 0-6-month group commonly having relatively high titers due to pre-existing maternal antibodies.
  
  
  CONCLUSIONS
  Our data suggest that Ad-based therapies may be suitible for children in the 7-12-month age range in this region.
authors.affiliation: National Engineering Laboratory for AIDS Vaccine, College of Life Science, Jilin University, Changchun, 130012, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Yu
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.forename: Jianing
authors.initials: J
authors.lastname: Dong
authors.forename: Chu
authors.initials: C
authors.lastname: Wang
authors.forename: Lina
authors.initials: L
authors.lastname: Gu
authors.forename: Caijun
authors.initials: C
authors.lastname: Sun
authors.forename: Wei
authors.initials: W
authors.lastname: Kong
authors.forename: Xianghui
authors.initials: X
authors.lastname: Yu
mesh_terms: D000258:Adenovirus Infections, Human / Q000453:epidemiology* / Q000821:virology; D000260:Adenoviruses, Human / Q000145:classification / Q000276:immunology*; D000367:Age Factors; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D016036:Seroepidemiologic Studies; D012703:Serotyping
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral